Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
Korean J Intern Med. 2013;28(3):314-321.   Published online 2013 May 1     DOI:
Citations to this article as recorded by Crossref logo
Synergistic Beneficial Effect of Docosahexaenoic Acid (DHA) and Docetaxel on the Expression Level of Matrix Metalloproteinase-2 (MMP-2) and MicroRNA-106b in Gastric Cancer
Najibeh Shekari, Mahsa Javadian, Mottahareh Ghasemi, Behzad Baradaran, Masoud Darabi, Tohid Kazemi
Journal of Gastrointestinal Cancer.2019;[Epub]     CrossRef
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(6): e0198544.     CrossRef
The role of third-line chemotherapy in recurrent or metastatic gastric cancer
Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Seung Soo Sheen
Medicine.2018; 97(39): e12588.     CrossRef
Advanced gastric cancer: is there an optimal chemotherapy regimen?
Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123.     CrossRef
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis
Wing-lok Chan, Kwok-keung Yuen, Steven Wai-kwan Siu, Ka-on Lam, Dora Lai-wan Kwong
Critical Reviews in Oncology/Hematology.2017; 116: 68.     CrossRef
Third-line chemotherapy in advanced gastric cancer
Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
Medicine.2017; 96(24): e6884.     CrossRef
Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
ESMO Open.2017; 2(3): e000206.     CrossRef
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Hugo Ford, Ioannis Gounaris
Therapeutic Advances in Gastroenterology.2015; 8(4): 189.     CrossRef
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim
World Journal of Gastroenterology.2015; 21(29): 8811.     CrossRef
Design of precise third-line therapy for gastric cancer: target or chemotherpy?
Jae Yong Cho
The Korean Journal of Internal Medicine.2013; 28(3): 297.     CrossRef